Human Biotech Animal Health 2019 | Kisaco Research
Innovating veterinary health with human biotechnology
Co-located with
Boston, USA
9 April, 2019
Download Agenda
The Audience
Watch Highlights

Series Highlights

   

Attendees at Boston 2018

Who attended Human Biotech & Animal Health

Why Attend

Join the 2nd Annual conference connecting human biotechs with the animal health industry.

Traditionally, innovation in veterinary health has come from parent human pharmaceutical R&D pipelines. Within an increasingly independent and mature animal health industry, new routes to innovation are being established. There are a multitude of exceptional technologies in the human health field that could be used in animal health, but currently there is limited contact between the two areas – this summit aims to connect the two industries.

Benefits of the Animal Health industry to Biotechs:

1st
Conference of its kind
120+
Attendees
15+
1-to-1 Meetings per person
6+

Testimonials

"This was an excellent event. As a newbie to animal health this was an eye opener. Some great connections and introductions. I would highly recommend your conference. The right balance of networking and information. Thank you!"

Sean Ekins, CEO, COLLABORATIONS PHARMA

 

"This conference provided relevant information and has led to a potential collaboration. I thought the conference was well focused. It was time well spent. I learned a lot and had productive networking sessions. The concept of the confluence of Human Biomedical development and Animal health is integral to our business plan. Kalos looks to leverage its proof of concept work as well as safety and tox to create parallel product lines."

George Colberg, CEO, Kalos Therapeutics, Inc.

 

"A well organized conference that established a strong link between biotechnology innovation and potential veterinary uses.”

Michael G. Palfreyman, Director, R&D Advisory Board, PAFOS PHARMA LLC

WHO SHOULD ATTEND?

HUMAN BIOTECHNOLOGY

Chief Executive Officers, Chief Scientific Officers, Chief Business Officers and corporate leadership from human biotechs working on technologies in fields including but not limited to:

 

ANIMAL HEALTH

-  Directors of External Innovation & Business Development from leading Animal Health Pharmaceutical and Nutrition Companies
-  Market Intelligence and Consultancy Providers

 

INVESTMENT & SERVICE PROVIDERS

-  Private Equity & Venture Capital Investors
-  Investment Bankers & M&A advisors
-  Legal Advisory

Benefits of Attending

FORGE RELATIONSHIPS with animal health executives and human biotechs in prescheduled 1-on-1 meetings, and discuss research collaborations, deallicensing and other business development opportunities

Address unmet and underserved medical needs across human and veterinary health

Human Biotechs

Identify the target disease areas in animal health that your human health assets can serve

Explore opportunities for generating non-dilutive income, validating and de-risking human research, and maximizing IP assets in our myth-busting case studies of human biotech and animal health partnerships

Learn about the different types of partnerships with animal health, such as research collaborations and out-licensing deals - and how these deals work

Animal Health

Form Partnerships with human health innovators to build your R&D and innovation pipeline.

Identify exciting new technologies in human health that may have translational potential for veterinary medicine - they might be the next blockbuster animal health products!

Hear what past attendees had to say:

Resources

Download Resource

We need some information to know where to send the link and how to address our email to you. Please note, a link to the PDF will also become immediately available once this form is submitted.

To prevent automated spam submissions leave this field empty.

Subject Access Requests: If you would like a copy of the data/information we hold about you, please email [email protected].

User Deletion Request: If you wish to have your information that is held by Kisaco Research deleted, please email [email protected].

For more information on Kisaco Research policy and procedures, please visit our Privacy Policy.

Speakers

 

Scott Brown

VP, Head of External Innovation
Zoetis

Scott Brown

VP, Head of External Innovation
Zoetis
 

Ailis Tweed-Kent

CEO
Cocoon Biotech

Dr. Ailis Tweed-Kent is an up-and-coming entrepreneur and leader in the development of innovative medical technologies. With her education in medicine at Harvard Medical School (HMS) and residency in internal medicine at Massachusetts General Hospital (MGH), Ailis has first-hand knowledge of the burden of disease. In 2013, Ailis was inspired by her patients to found Cocoon to develop innovative silk therapeutics for osteoarthritis.

Ailis Tweed-Kent

CEO
Cocoon Biotech

Dr. Ailis Tweed-Kent is an up-and-coming entrepreneur and leader in the development of innovative medical technologies. With her education in medicine at Harvard Medical School (HMS) and residency in internal medicine at Massachusetts General Hospital (MGH), Ailis has first-hand knowledge of the burden of disease. In 2013, Ailis was inspired by her patients to found Cocoon to develop innovative silk therapeutics for osteoarthritis. Prior to Cocoon, she worked on the design, development, and delivery of diagnostic technologies for global health collaborating with organizations such as PEPFAR/Office of U.S. Global AIDS Coordinator, London School of Hygiene & Tropical Medicine, and the Global Health Delivery Project. She brings a multidisciplinary approach with a B.S. in Chemical Engineering from the University of Notre Dame.

 

Peter Hanson

Chief Veterinary Officer and EVP Clinical Operations & CMC
Centrexion Therapeutics

Centrexion is developing a pipeline of non-opioid, non-addictive treatments to manage pain in people and animals.  Peter started his career as a practicing veterinarian and has spent the last 21 years in industry.

Peter Hanson

Chief Veterinary Officer and EVP Clinical Operations & CMC
Centrexion Therapeutics

Centrexion is developing a pipeline of non-opioid, non-addictive treatments to manage pain in people and animals.  Peter started his career as a practicing veterinarian and has spent the last 21 years in industry. At Merck and then Merial he was the project leader for two global programs that led to new pain management products for osteoarthritis in dogs and horses.  He subsequently held leadership roles for pharmaceutical R&D and project & portfolio management before moving to Abbott Animal Health where he was head of R&D & medical affairs.  Peter received his BA and DVM from the University of Minnesota and completed a large animal surgical residency, MS and PhD at the University of Wisconsin-Madison.

 

Lewis Gruber

CEO
SIWA Therapeutics, Inc.

Lewis Gruber is Chief Executive Officer and a founder of SIWA Therapeutics, Inc. (“SIWA”). SIWA is a pre-clinical stage biopharmaceutical company with a first-in-class humanized monoclonal antibody (“mAb”) that binds to a SIWA-identified advanced glycation endproduct target antigen on senescent cells (“SCs”) and removes them. SCs accumulate with aging or exposure to stress and have a causative role in age-related dysfunction and degenerative diseases including.

Lewis Gruber

CEO
SIWA Therapeutics, Inc.

Lewis Gruber is Chief Executive Officer and a founder of SIWA Therapeutics, Inc. (“SIWA”). SIWA is a pre-clinical stage biopharmaceutical company with a first-in-class humanized monoclonal antibody (“mAb”) that binds to a SIWA-identified advanced glycation endproduct target antigen on senescent cells (“SCs”) and removes them. SCs accumulate with aging or exposure to stress and have a causative role in age-related dysfunction and degenerative diseases including. by way of example, many cancers, and neurodegenerative diseases such as Parkinson’s, ALS, and Alzheimer’s Disease, SIWA has the complete sequence of SIWA 318H, which provides the basis for senescent cell clearance in any mammalian species. Prior to founding SIWA, Mr. Gruber was a founder of Arryx, Inc., and served as its CEO from 2000 through 2005 (acquired by a publicly-held company).  While Mr. Gruber was at Arryx, it received numerous awards including ones for World Economic Forum Technology Pioneer (2005) and Red Herring Top 100 Innovator for 2004.  Prior to Arryx, he was a founder of Hyseq, Inc, a publicly-held genomics company (subsequently merged). He served as Hyseq’s CEO from 1994 through 2000. While CEO, Hyseq completed the largest IPO of a biotechnology company in 1997 (underwritten by Salomon Smith Barney and others) and obtained collaborations for Hyseq totaling over $10 million. The technology was sold to Beijing Genomics Institute. 

 

George Colberg

CEO
Kalos Therapeutics

George Colberg

CEO
Kalos Therapeutics
 

Jed Hubbs

CEO
Neurocycle Therapeutics

Jed Hubbs

CEO
Neurocycle Therapeutics
 

Sharon Chase

Regulatory Group
Schafer Veterinary Consultants

Dr. Sharon Chase is a small animal veterinarian with over a decade of clinical practice experience gained from working in general and emergency hospitals in Massachusetts and Washington, DC. In addition to clinical practice, Dr. Chase served as a reviewer with the Food and Drug Administration's Center for Veterinary Medicine (CVM) for over seven years. She currently works as a regulatory consultant for the veterinary pharmaceutical industry with Schafer Veterinary Consultants, based in Fort Collins, Colorado.

Sharon Chase

Regulatory Group
Schafer Veterinary Consultants

Dr. Sharon Chase is a small animal veterinarian with over a decade of clinical practice experience gained from working in general and emergency hospitals in Massachusetts and Washington, DC. In addition to clinical practice, Dr. Chase served as a reviewer with the Food and Drug Administration's Center for Veterinary Medicine (CVM) for over seven years. She currently works as a regulatory consultant for the veterinary pharmaceutical industry with Schafer Veterinary Consultants, based in Fort Collins, Colorado.

 

Chris Robillard

Director, Business Development
Karyopharm Therapeutics

Chris has spent the last 3 years in business development at Karyopharm helping to advance clinical stage products to commercialization in both the human and animal oncology settings. Karyopharm has tested multiple products in canine oncology, both to inform clinical design in humans and to seek partners to advance products in canine oncology. Chris has spent the over 10 years in pharma/biotech in various business development and financial roles.

Chris Robillard

Director, Business Development
Karyopharm Therapeutics

Chris has spent the last 3 years in business development at Karyopharm helping to advance clinical stage products to commercialization in both the human and animal oncology settings. Karyopharm has tested multiple products in canine oncology, both to inform clinical design in humans and to seek partners to advance products in canine oncology. Chris has spent the over 10 years in pharma/biotech in various business development and financial roles.

Media Partner

Agenda at a Glance

You can download our first-look agenda here.

Simply fill in this form and we'll send you a PDF version immediately. We need some information to know where to send the file and how to address our email to you.

Forge relationships; Identify exciting new technologies; Learn about the different types of patnerships available to you

Headline speakers include:

Download Agenda

We need some information to know where to send the link and how to address our email to you. Please note, a link to the PDF will also become immediately available once this form is submitted.

To prevent automated spam submissions leave this field empty.

Subject Access Requests: If you would like a copy of the data/information we hold about you, please email [email protected].

User Deletion Request: If you wish to have your information that is held by Kisaco Research deleted, please email [email protected].

For more information on Kisaco Research policy and procedures, please visit our Privacy Policy.

Conference Packages

Sending Your Team? Group Discounts Available!

Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates

Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off

If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920

Thursday, November 1, 2018 to Saturday, February 2, 2019
Start-Up Pass
$699
Super Early Bird rate until Feb 1st (Standard price $899)
Email Jessica to register at this price: [email protected]
Emerging Companies (Pharma & Biotech, under $10 million in annual revenue)
Venture Capital and Angels
Academics
+ $499 to attend Animal Health Investment USA as well (April 10-11)
Thursday, November 1, 2018 to Saturday, February 2, 2019
Delegate Pass
$1,599
Super Early Bird rate until Feb 1st (Standard price $2,199)
Human Biotechs
Animal Health Companies
Pharmaceutical Companies
Companies over $10 million in annual revenue
+ $499 to attend Animal Health Investment USA as well (April 10-11)
Thursday, November 1, 2018 to Saturday, February 2, 2019
Multinational Pass
$1,999
Super Early Bird rate until Feb 1st (Standard price $2,499)
Companies over $100 million in annual revenue
+ $499 to attend Animal Health Investment USA as well (April 10-11)
Thursday, November 1, 2018 to Saturday, February 2, 2019
Service Provider Pass
$2,099
Super Early Bird rate until Feb 1st (Standard price $2,899)
CROs & CMOs
Consultants
Private Equity
+ $499 to attend Animal Health Investment USA as well (April 10-11)
Preparing registration...

Book a Team to Save More!

Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off

Payment Terms for Animal Health Investment Europe:

  • Please note that a $79 processing fee will apply to any invoices requested.
  • Any questions about your registration, please call +44 (0)20 3696 2920 or email us at [email protected].
  • All Prices are in USD
  • All Early Bird discount prices, including Group Discounts, must be paid in full by deadlines provided above.
  • No discounts or offers can be combined.
  • Those offering consultancy or market intelligence services do not qualify for the Start-Up rate.
  • PLEASE NOTE – no additional discounts are available on ‘Start-up Company’ pricing. Group discounts are ONLY available on ‘Delegate’ pricing.
  • You can view our Cancellation Policy here.

Become a Sponsor

Kisaco Research provides the much needed platform on which industry executives can network, connect and learn from each other as well as meet potential industry partners.

Far from the typical ‘meet-and-greet’ exhibition experience, you – as a sponsor or exhibitor – will be positioned as a partner of the event with a focus on the benefits of your product and brand, rather than just a name on an exhibition list.

With our extensive marketing experience and strategy, your partnership with Kisaco Research will grant you a sponsorship package that is an extension and enhancement of your current marketing and branding efforts. We value your ROI and will work with you directly on your specific goals and targets – that’s why we take special care in finding the most relevant end-users to attend, so that your financial and resource investment is smartly allocated.

Find out more by calling us at +44 (0)20 3696 2920 or email us at [email protected].

About Kisaco Research

Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.

Meet industry peers that will help build a career-changing network for life.

Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.

Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.

Invest both in your company growth and your own personal development by signing up to one of our events and get started.

Contact Us

We need some information to know how best to respond to your request below.

To prevent automated spam submissions leave this field empty.

Subject Access Requests: If you would like a copy of the data/information we hold about you, please email [email protected].

User Deletion Request: If you wish to have your information that is held by Kisaco Research deleted, please email [email protected].

For more information on Kisaco Research policy and procedures, please visit our Privacy Policy.

Other events you might be interested in:

Animal Health USA 2019